[Market Movement Analysis] Illumina surges on September 17: Added to S&P 500, UBS upgrade, and strong NovaSeqX demand

1. On September 4, S&P Dow Jones Indices announced that Illumina is set to be added to the S&P 500 Index before the market opens on September 21, replacing Builders FirstSource, meaning index-tracking funds may need to adjust their holdings to include the new constituent stock.
2. On September 9, UBS upgraded Illumina's rating from "Neutral" to "Buy," and raised the target price from $135 to $260; the company’s closing price on September 8 was $211.06.
3. On September 8, data showed that Illumina primarily focuses on gene sequencing technology, and demand for NovaSeq X remains high more than three years after its launch, with over 95 new units installed last quarter. The company expects organic revenue growth of over 5% year-on-year in other global regions for the full year.

(Disclaimer: This content is collected and summarized from public information by AI technology and is for reference only. It does not constitute investment advice.)